New Coverage for Periodontal Medicament Carrier D5994

Perio Trays by Perio Protect

www.PerioProtect.com

Perio Protect, LLC

Chief Scientific Officer

Two Dental Benefits providers, Companion Life and Kansas City Life, have both recently announced coverage for a custom periodontal medicament tray code D5994.

Peroxide delivered deep with the tray overcomes these antibiotic limitations for long-term gingival health.”

— Duane C. Keller, DMD, FAGD

SAINT LOUIS, MISSOURI, USA, February 1, 2017 /EINPresswire.com/ — Two Dental Benefits providers, Companion Life and Kansas City Life, have both recently announced coverage for dental procedure code D5994 documenting a periodontal medicament carrier, a custom-fabricated tray used to deliver medication into periodontal pockets.

Initial reviews of insurance claim data for patients who have received Perio Trays® indicate that this benefit translates into better treatment outcomes for patients and a reduction in longer-term health costs. For companies that provide both dental and medical insurance, the savings in health care costs are expected to multiply given that treatment for periodontal disease has been shown to reduce overall healthcare costs for patients with diabetes, cardiovascular diseases, and pregnancy.

The most common periodontal medicament delivery device available to patients is the Perio Tray. Perio Trays have an internal peripheral seal and are proven to deliver medication deep into periodontal pockets to fight infections between office visits. Patients can only obtain a prescription Perio Tray through a licensed dentist who will develop and monitor a treatment plan for individual patients.

Perio Trays are used adjunctively to provide the best homecare. Toothbrush, rinse and floss can’t reach deep enough into periodontal pockets to help the 46% of Americans adults with chronic periodontitis. The Perio Tray has been shown to place medication into shallow and deep pockets to reduce inflammation and pocket depths when used in 15-minute daily applications.

“The key with prescription tray therapy” says Dr. Duane Keller, the inventor of the Perio Tray, “is to use a low concentration of peroxide to oxygenate the pockets, kill anaerobic bacteria, and change the microenvironment to create conditions for healthy bacterial regrowth. We used to provide antibiotics, but their benefits were largely temporary. Peroxide delivered deep with the tray overcomes these antibiotic limitations for long-term gingival health.”

Doug Dunlap
Perio Protect
314-256-0772
email us here

Perio Trays Reach Bacteria Toothbrushes Can’t


Source: EIN Presswire

Nutrition For Healing Launches Nationwide Sarcopenia Study



MEND Regenerate Medical Dietary Supplement For Sarcopenia

Study will measure the benefits of award winning MEND Regenerate on age-related muscle loss, frailty and improvement in strength and stability

With NSF Sport certification and the continuous research and studies we are running, our customers know they are getting the best products available in functional nutrition.”

— Sheraz Syed, P.T., CSCS, MDT

NEW YORK, NEW YORK, UNITED STATES, January 31, 2017 /EINPresswire.com/ — Nutrition For Healing® LLC announces that it will commence a double blind placebo study of award winning MEND Regenerate to validate efficacy in combating aging-related muscle loss, a condition called sarcopenia which affects 50% of the elderly.

“We’re an evidence based company that relies on strong science in developing our products” says healthy aging expert and science advisory board member Ken Roycroft, “Regenerate was developed after two years of testing in a busy orthopedic and sports medicine practice and we have continued to experience tremendous results with our patients. This study will further validate its efficacy.”

MEND™ Regenerate is focused on combating aging-related muscle loss, a significant health issue which negatively impacts strength, stamina, mobility, balance and overall vitality. Humans begin losing muscle mass as early as their 30s. Many of us find this defeating after spending our first three decades of life easily gaining muscle mass. Alarmingly, we can lose as much as 3 to 5 percent of muscle mass per decade. This can lead to an increased risk of bodily injury after 30 and a vicious cycle of decline. Some muscle mass loss is natural but accelerated muscle mass loss can and should be prevented.

There are a number of factors that contribute to aging-related muscle loss including lack of resistance exercise, reduction in hormones and poor nutrition. Because muscles begin synthesizing protein differently as we age, we need to take in not only more protein, but different protein, especially proteins that digest quickly. Proteins that reach the body sooner are able to heal muscles more quickly after exercise, reducing the risk of loss. MEND™ Regenerate has been formulated specifically to get healthy fast absorbing proteins and other vital nutrients into the body.

“With the combination of our certifications such as NSF Sport and the continuous research and studies we are running, our customers know they are getting the best products available in functional nutrition,” says physical therapist and strength and conditioning expert Sheraz Syed “we look forward to publishing results from this important study and continuing to build strong science around our products.”

Jasmine Smith
Nutrition For Healing
9174889897
email us here


Source: EIN Presswire

Big Data Market: Embracing Data to Transform Healthcare By Key Trends,Technologies,and Increase in Business Performance

Big Data For Healthcare has been prepared based on an in-depth market analysis with inputs from industry experts.

SUITE 600, DALLAS, TEXAS, UNITED STATES, January 31, 2017 /EINPresswire.com/ — Summary

Orbis Research Inclusive Report Big Data: Embracing Data to Transform Healthcare and Pharma Commercial Strategy-Featuring Expert Panel Views from Industry Survey 2016 has been prepared based on an in-depth market analysis with inputs from industry experts.

Description

Orbis Research’s latest report," Big Data Market: Embracing Data to Transform Healthcare and Pharma Commercial Strategy – Featuring Expert Panel Views from Industry Survey 2016" provides a comprehensive analysis of the Big Data landscape. GBI Research conducted an extensive industry survey of 73 experts from the pharmaceutical and healthcare industries – including both organizations that already utilize Big Data and those that do not. Our survey gathered experience and opinion on the use of Big Data, and insights on key trends for the present and future use of the technology within healthcare. The findings from the survey and results from secondary research efforts have been amalgamated with GBI’s own analytical views to provide an assessment that is comprehensive in outlook.

Big Data refers to any data set that is too large to store, process or analyze using traditional database software and hardware. It can have a significant impact on all aspects of the pharmaceutical and healthcare sector, and companies are making large investments to leverage the technology more effectively. Big Data has been a buzzword for many years, but it is no longer merely an abstract concept that could provide future benefits, as it is already providing competitive advantages for a variety of organizations. As such, companies that ignore its potential may fall behind their peers in our increasingly data-intensive world.

Get a PDF Sample of Big Data: Embracing Data to Transform Healthcare and Pharma Commercial Strategy Market Report at: http://www.orbisresearch.com/contacts/request-sample/179457

The report features an overview of Big Data and its place within healthcare. It examines the factors driving and necessitating the use of the technology within this industry, and provides detailed examples of how different Big Data sources and analytics techniques could be used to provide direct benefits to pharmaceutical companies, healthcare institutions and patients. There is also an analysis of the main challenges surrounding the technology, as well as detailed real-world case studies of how major companies already implement Big Data and deal with some of the challenges. Finally, based upon the totality of our survey results and research, strategic recommendations and guidelines are provided for the effective implementation of Big Data within healthcare.

The results of GBI’s latest industry survey provide insightful analyses from different expert panels, including those that already use Big Data and those that do not, key regional markets, and respondents from within the pharmaceutical industry and those from the wider healthcare industry. The survey examined key issues, such the areas where organizations are currently utilizing Big Data, where they believe it can have the most impact, the main barriers to use and driving factors, likelihood of increasing investment within the next five years, and overall stance on the use of the technology within healthcare.

GBI Research conducted extensive research in order to provide a comprehensive view of Big Data for healthcare landscape. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising areas in the market and exploit key business opportunities.

Place a Purchase Big Data: Embracing Data to Transform Healthcare and Pharma Commercial Strategy Market Report at: http://www.orbisresearch.com/contact/purchase/179457

Scope

– What is Big Data? What is its place within healthcare, and what are the main data sources?
– How prevalent is the use of Big Data in healthcare?
– What are the main driving factors necessitating the use of Big Data in healthcare? What is the relative importance of these factors according to industry?
– What are examples of the commercial benefits that the use of Big Data and analytics can provide, in different aspects of the industry?
– In which areas are organizations currently using Big Data, and where do they feel it will have the most impact in the next five years?
– What are the main challenges associated with Big Data in healthcare? What is the relative importance of these factors according to industry? For the organizations that do not yet utilize Big Data, what specific reasons have led to their decision not to do so?
– How do major pharmaceutical and healthcare companies use Big Data in the real world? What are some of the main partnerships between Big Pharma and technology companies? What is the underlying technical architecture of Big Data in healthcare?
– What is the likelihood that organizations that already use Big Data will increase their investment within the next five years? Will those that do not currently invest in the technology begin doing so in the next five years?
– How can Big Data be effectively implemented within an organization?
– What is the overall stance of various experts in the healthcare field on the use of Big Data in healthcare?

Key Reasons to Purchase

This report will allow you to –
– Gain insightful analyses and comprehensive understanding of Big Data in healthcare
– Understand the key drivers necessitating the use of Big Data and the main barriers to implementation
– Understand the views of 73 organizations within the industry on Big Data, and assess real-world case studies
– Assess the most relevant uses of Big Data within your company, and effective ways of implementing Big Data strategies

Some Points From TOC:

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7

2 Big Data Overview 9
2.1 What is Big Data? 9
2.2 The ‘Three Vs’ of Big Data: Volume, Velocity and Variety 9
2.3 The Sources of Big Data in Healthcare 10

3 Drivers of Big Data in Healthcare 17
3.1 Advances in Technology: Explosion in Data Generation 17
3.1.1 Next-Generation Sequencing Technologies: Outpacing Moore’s Law 17
3.1.2 Proteomic Databases: ProteomicsDB Designed with Big Data Analytics in Mind 18

4 Commercial Implications of Big Data in Healthcare 27
4.1 Predictive Modeling: Fundamental Source of Big Data’s Power 27
4.1.1 Using Big Data for Patient-Specific Modeling: Potential for Huge Healthcare Savings 28
4.2 Big Data Unlocks the Potential of Personalized Medicine and Targeted Therapies 28

5 Challenges Associated with Big Data in Healthcare 38
5.1 Data Quality: Analysis Output Can Only Be as Good as the Data Input 38
5.1.1 Does “Messy” Real-World Data Have a Place in Evidence-Based Medicine? 38
For any enquires before buying, connect with us @ enquiry@orbisresearch.com

Hector Costello
Orbis Research
+1 (214) 884-6817
email us here


Source: EIN Presswire

International Doulagivers Institute Announces Free Family Caregiver Training for Global Outreach Initiative

Suzanne B. O’Brien R.N. and Founder of Doulagivers

Suzanne B. O’Brien teaching the Level 1 End of Life Doula Community Training in Guilford, CT last year.

Doulagivers will be offering Webinars, E-book and Live Workshops for their FREE family caregiver training.

Doulagivers has launched a global initiative on supporting families everywhere with a free training on how to care for a dying loved one.”

— Suzanne B. O'Brien R.N.

NEW YORK CITY, NEW YORK, UNITED STATES, January 31, 2017 /EINPresswire.com/ — Doulagivers, the leader of specialized training in End of Life Care and End of Life Doulas is offering new ways to access their free Level 1 Family Caregiver Training. As part of the Doulagivers Level 1 Global Outreach and Community Caregiving Initiative, this training will be offered for FREE through live webinars (starting March 7th, enrollment open now), through their E-book 'Creating Positive Passings: End of Life Doula, Level 1 Caregiver Training' which is available for FREE on Amazon until Saturday, February 4th and through Live Workshops offered at the International Doulagivers Institute in NYC. Doulagivers' main goal is to spread awareness of the need for communities to become involved in the volunteer work necessary to ensure that everyone can have a peaceful end of life experience. Hospice workers are stretched beyond their means and there are too many patients all over the world who are incapable of receiving the 24/7 care required at end of life to create a sacred, meaningful and pleasant transition from the physical world. This Level 1 training is designed so that anyone and everyone can understand the basic end of life processes and how to suggest and offer comfort to families and patients throughout these processes. Doulagivers believes that it is imperative that everyone has the basic knowledge to offer support within their communities at this precious last phase of life. If everyone can contribute a little bit of time and compassion, it relieves so much burden from the caregivers and families so that facilitating a good death for every end of life patient around the world becomes possible.

In the Level 1 Training you will learn:

1. How to identify the Shock Phase and what suggestions for comfort can be given
2. How to identify the Stabilization Phase and what suggestions for comfort can be given
3. How to identify the Transition Phase and what suggestions for comfort can be given
4. How to interact with patients at end of life
5. How to offer emotional support for grieving families during and after death

Doulagivers was recently featured in CBS. You can watch the segment and read the article here.

For those who wish to become full-time End of Life Doulas and pursue a career in this field, Doulagivers also offers a comprehensive Certification/Practitioners course. The End of Life Doula Certification training is for those who wish to be Certified End of Life Doulas. This course covers Levels 1,2&3 of the Doulagivers End of Life Practitioners training. This is a new specialized area of non-medical health care. This Training is for those who have a calling and desire to support and guide both patients and families through the end of life process. Following in the footsteps of the birthing doula movement that has been a successful specialized non-medical field in the area of childbirth for decades, now is the time for us to offer the same care and support for those at end of life. This course is offered completely online or as a monthly workshop at the International Doulagivers Institute.

All live workshops at the International Doulagivers Institute will be limited to 10 students to ensure optimal learning. All trainings are conveniently available online as well so that you can take them from anywhere in the world.

Upcoming Dates for the End of Life Doula Certification training held at the International Doulagivers Institute in NYC:

March 26th, 2017 9am-5pm
April 30th, 2017 9am-5pm
May 21st 9am-5pm
June 25th 9am-5pm

For more information on these trainings, visit their website, email Doulagivers@gmail.com or call 1-646-883-6534.
#EOL #Endoflifedoulatraining #Hospice #Deathdoulatraining #Endoflifeguide

Suzanne O'Brien
Doulagivers
845-337-0389
email us here


Source: EIN Presswire

Can multi-organ-on-a-chip technologies lead to a paradigm shift in drug development?


Drug Discovery 2017 | Register at www.drug-discovery.co.uk

Drug Discovery 2017 | Register at www.drug-discovery.co.uk

TissUse Head of BD to lead talk on the impact of Multi-organ-chip technologies on drug discovery.

LONDON, ENGLAND, UNITE, January 31, 2017 /EINPresswire.com/ — TissUse, leading pioneers of the Multi-Organ-Chip technology, will be joining the expert speaker lineup for SMi Group's exclusive conference on Drug Discovery. The event will be launched on the 27th and 28th of April 2017 in London.

TissUse’s proprietary multi-organ-chip technology platform closely emulates and simulates human biology to achieve uniquely lifelike environments. Connected organs and close physiological context allow remarkably close resemblance to in vivo conditions. This has benefited the drug development process, with current in vitro and animal modelling tests failing to emulate physiological organ complexity within the human body.

Head of Business Development, Reyk Horland, will be leading a spotlight session on multi-organ-chip technologies and its potential impact on drug discovery at the conference.

Reyk's presentation will showcase how "human-on-a-chip" technology is transforming drug development. He will demonstrate how this new approach allows us to closely study organoid interaction and allows more representative drug toxicity and efficacy screening. He will also highlight the importance of highly physiologically relevant cultures and microenvironments as scientists aim to close the gap between in vivo and in vitro.

Reyk will be speaking on Day 2 of the conference and joins lead decision-makers and industry innovators from Sanofi, Takeda, AstraZeneca, Merck Serono, AbbVie, GSK, Johnson & Johnson, UCB Pharma, Eli Lilly and more. A full list of speakers can be found on www.drug-discovery.co.uk/EIN.

SMi’s Drug Discovery conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.

The event will also feature two post-conference workshops on new approaches in lead generation and applications of physicochemical and biomimetic properties in early drug discovery.

For more details about the conference and to register, visit www.drug-discovery.co.uk.

DRUG DISCOVERY
27 – 28 MARCH 2017
Holiday Inn Kensington Forum
www.drug-design.co.uk

—end —

Contact Information:

For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Fateja Begum at fbegum@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Honey de Gracia
SMi Group Ltd
+44 (0)20 7827 6102
email us here


Source: EIN Presswire

Utah Mesothelioma Victims Center Now Urges a Diagnosed Oil Refinery Worker in Utah to Call for Instant Access to The Nation's Top Lawyers for A Free Compensation Evaluation

Before you hire a lawyer or a firm to assist with a mesothelioma claim for a diagnosed person anywhere in Utah please call us at 800-714-0303”

— Utah Mesothelioma Victims Center

NEW YORK, NEW YORK, USA, January 31, 2017 /EINPresswire.com/ — The Utah Mesothelioma Victims Center is now urging a current or former oil refinery worker in Utah who has recently been diagnosed with mesothelioma or their family members to call them anytime at 800-714-0303 for instant access to some of the nation's most skilled mesothelioma attorneys who actually have experience helping oil refinery workers with this rare cancer get properly compensated. http://Utah.MesotheliomaVictimsCenter.Com

The Utah Mesothelioma Victims Center says, "Next to US Navy Veterans or skilled trades workers-oil refinery workers exposed to asbestos at a refinery in Utah or another state are one of the top work groups for mesothelioma in Utah each year. Oil refinery workers typically should get the best possible financial compensation for this rare cancer caused by asbestos exposure but without the nation's most skilled and experienced mesothelioma attorneys-the best possible compensation probably will not happen as we would like to discuss anytime at 800-714-0303." http://Utah.MesotheliomaVictimsCenter.Com

Vital Mesothelioma Compensation Tip from the Utah Mesothelioma Victims Center: "If you wanted someone to run an oil refinery or to maintain it you would not hire someone with no experience in the operation of something as complex as a refinery. Why then hire a local car accident lawyer with little to no experience handling complex mesothelioma compensation claims involving oil refineries or power plants? Before you hire a lawyer or a firm to assist with a mesothelioma claim for a diagnosed person anywhere in Utah please call us at 800-714-0303." http://Utah.MesotheliomaVictimsCenter.Com

The Utah Mesothelioma Victims Center would like to emphasize theirs is a statewide initiative available to a diagnosed victim anywhere in Utah including communities such as Salt Lake City, Provo, West Jordan, Sandy Hills, Ogden, Saint George.

For the best possible mesothelioma treatment options in Utah the Utah Mesothelioma Victims Center strongly recommends the following heath care facility with the offer to help a diagnosed victim, or their family get to the right physicians at this hospital.

* The Huntsman Cancer Institute in Salt Lake City: http://healthcare.utah.edu/huntsmancancerinstitute/

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. However-mesothelioma does happen in Utah.

High risk work groups for exposure to asbestos in Utah include US Navy Veterans, power plant workers, plumbers, electricians, auto mechanics, machinists, or construction workers. In most instances a diagnosed person with mesothelioma was exposed to asbestos in the 1950’s, 1960’s, 1970’s, or 1980’s.

The Utah Mesothelioma Victims Center says, “When it comes to obtaining the best mesothelioma settlement, the quality of the attorney matters, as we would like to explain anytime at 800-714-0303.” http://Utah.MesotheliomaVictimsCenter.Com

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer: http://www.nlm.nih.gov/medlineplus/mesothelioma.html

Michael Thomas
Utah Mesothelioma Victims Center
800-714-0303
email us here


Source: EIN Presswire

AstoriaLeads.com for Insurance Agents and Carriers


Astoria Leads

Insurance Leads

Exclusive and Shared Insurance Leads

Exclusive and Shared Insurance Leads”

— Scott Thompson

DUBLIN, CALIFORNIA, UNITED STATES, January 31, 2017 /EINPresswire.com/ — Astoria Company announces major upgrade to its insurance agent lead platform, AstoriaLeads.com

California, January 2017 – Adding to their vast portfolio of performance marketing technology, AstoriaLeads.com offers insurance agents and carriers in Auto, Home, Life, & Health insurance the opportunity to acquire new customers with real-time exclusive & shared leads.

Scott Thompson, CEO stated; “we wanted to create a complete self-service platform that would take down barriers that once blocked Agent’s ability to get the most productivity out of their advertising dollars by putting the Agent in the driver seat. Agents can now receive exclusive or shared leads that target their desired geographical areas with no blocked zip codes or limits of territories or states.”

This new innovative platform provides insurance Agents the ability to set their daily/ and or hourly buying caps to the rate that their resources can manage.

All leads delivered in real-time, complete with the full consumer information collected at source, allowing Agents to save time and get more results for their investment. Leads can be delivered directly in the Agent’s CRM, text message and email.
Astoria Company owns, operates and manages a multitude of internet properties to ensure the widest reach to generate organic leads. All of their Exclusive Leads are guaranteed to sell to only one buyer! And Shared Leads are guaranteed to be sold to no more than four.

By going to http://www.AstoriaLeads.com, Insurance agents and carriers can sign up online and start receiving leads right away.

Astoria owns a proprietary lead exchange platform for many B2C verticals which process over 50 million web and mobile leads per month as well as 200+ pay per call lead generation campaigns. In addition, Astoria powers websites for Domain Investors who care about maximizing profits and creating a successful online presence, going way beyond traditionally parked domains. Coming soon will be the launch of DomainParking.com which is intended to disrupt and redefine the very definition of domain parking. Astoria Company was recently recognized as one of The Top 50 Most Admired Companies of the Year by the Silicon Review.

CONTACT: Scott Thompson, CEO Scott@AstoriaCompany.com

Scott Thompson
ASTORIA COMPANY
15106637016
email us here


Source: EIN Presswire

Is Modular Laboratory Furniture Really More Expensive Than Fixed Casework?

Fixed Casework in U.S. Army Food DiagnosticLab

Modular Lab – Sample Processing

After reviewing many fixed casework & modular laboratory furniture projects; this article compared pros and cons under 4 main subjects. Review them now!

Point 3: Cost is an issue. As it turns out, modular designs are often cheaper than fixed casework installations.

— Formaspace

AUSTIN, TEXAS, UNITED STATES, July 25, 2016 /EINPresswire.com/ — In the laboratory field, there is a major trend underway toward modular lab furniture, yet many assume that modular designs are more expensive than traditional fixed casework. We investigate the facts about modular versus fixed casework.

In this brief buyer’s guide, we uncover the many reasons that modular laboratory furniture is becoming more popular — such as modular furniture’s lower installation costs — which generally make it less expensive than fixed casework projects.

But before we jump into the side-by-side comparison, we want to be clear: Formaspace sells BOTH modular lab furniture AND fixed casework. We’ve got you covered either way.

In fact, we recently completed construction of the largest food and diagnostics lab in the U.S. at Fort Sam Houston in San Antonio, Texas for the Department of Defense’s Food Analysis and Diagnostic Laboratory (FADL).

So if your preference is for fixed casework, there’s no doubt about it — we have the solution you need.

But modular furniture is coming up fast, so we’d like to share with you what we’ve learned from over 30 years of experience in working with laboratories, and why the market is making the move to modular furniture designs.

Our research and experience shows there are four key points to consider when deciding between fixed casework and modular furniture.

Point 1: The lab you build or renovate today will evolve considerably during its useful life.
Constant change is the watchword in today’s modern life science and research laboratories. In particular, lab designers should pay attention to these three:

– changes in technology
– the hunt for scarce talent
– major real estate trends

First, a word about technology. It’s getting more sophisticated and powerful, often smaller, sometimes cheaper (but not always). At the same time, the continuous roll out of new technologies is leading many to reconfigure their lab facilities far sooner than they anticipated in order to keep pace with the latest scientific advances.

The big advantage for modular lab furniture is that it simplifies re-configuring your lab. With modular furniture you can move cabinets around — even change your entire floorplan — to improve traffic flow, accessibility, etc. Modular furniture also allows you to easily increase your storage density by adding more shelves and cabinets to your existing installation.

On the other hand, fixed casework makes it much more difficult to change anything about your lab layout. Even small alterations can result in complicated, time-consuming, and disruptive construction projects.

As the healthcare, life sciences, and research industries continue to grow, recruiting top talent has become another concern that lab designers and space planners need to take into account. As in other tech industries, the best and brightest graduates have new ideas about how they want to collaborate in the workplace, as exemplified by emergence of non-traditional

Real estate trends are another important consideration. In the established life science research clusters like Boston, Raleigh-Durham, New York / New Jersey, the Bay Area, Los Angeles, and San Diego, occupancy rates are very high, which has driven up commercial rents for lab space to new highs. At the same time, mergers and acquisitions are on the increase.

The upshot is that if your lab has a favorable lease (or you own your real estate), you may be facing increasing pressure to accommodate more people and equipment in your existing location due to the high cost of relocation or expansion. In this case, modular furniture solutions make it far easier to increase the efficiency of your current setup. It’s very straightforward to add new workspaces and additional storage components, which is difficult to achieve with traditional fixed casework.

CONCLUSION 1: To keep up with technology, talent, and real estate space planning trends, modular lab furniture has the advantage in flexibility because re-configuring your facility is much easier compared with traditional fixed casework designs.

Advantage: Modular

Point 2: Chances are increasing that your entire lab operation will need to move to a new location one day.

A report on trends in the life sciences market by the real estate consultancy Jones Lang LaSalle (JLL) confirms that overall growth, along with industry consolidation and globalization, is resulting in shortages of available high-quality lab space in the key life science clusters around the nation.

In the Cambridge / Boston area, which has the highest concentration of laboratory research activity in the U.S., the real estate consultancy CRBE reports that lease rates are at a record high and there is little inventory for expansion.

This phenomenon is replicating itself across the nation. As a result, many laboratory research companies in major cluster centers like Cambridge / Boston, the Research Triangle in North Carolina, San Francisco, and Los Angeles are now actively looking at:

– renovating non-traditional buildings to build out new laboratories
– relocating to suburban locations where rents are cheaper and space is available
– moving away from expensive cluster cities to secondary markets, such as Philadelphia

Read more… https://formaspace.com/articles/laboratory-furniture/modular-laboratory-furniture-vs-fixed-casework/?utm_source=einpresswire&utm_medium=content&utm_campaign=article-062016

Mehmet Atesoglu
Formaspace
8002511505
email us here


Source: EIN Presswire

Goodyear, Arizona Dentist Selected to the "America's Best Dentists" 2017 Directory

George R. Ayoub DDS, MICOI, MAAIP, DICOI.

Dr George R. Ayoub Listed as Top Dentist in Family, Cosmetic, Implant & Sedation Dentistry

Dr. George Ayoub Selected as Top Dentist in Family, Cosmetic, Implant & Sedation Dentistry

— TodaysBestDentists.com

GOODYEAR, ARIZONA , UNITED STATES, January 16, 2017 /EINPresswire.com/ — Goodyear, Arizona dentist, Dr. George R. Ayoub has been selected to the "America's Best Dentists" registry for 2017. Selections were made by the National Consumer Advisory Board, an organization that identifies top professionals in their fields.

Dr. Ayoub practices Family, Cosmetic, Implant and Sedation Dentistry at 14150 West Mcdowell Road in Goodyear, serving patients in Avondale, Pebble Creek, Buckeye, Phoenix, Goodyear, Tolleson, Litchfield Park and Surprise.

Services include: Dental Implants, Cosmetic Dentistry, Veneers, Same-Day Crowns, Temperomandibular Joint Disorders (TMJ), General Anesthesia, Composite and Porcelain Bonding, Zoom Whitening, Dentures, Partial Dentures, Hollywood Smiles and Full Mouth Reconstruction.

Dr. Ayoub received his Doctor of Dental Surgery degree (DDS) from the University Of Southern California School of Dentistry, where he also served as an instructor. He has earned numerous awards for continuing education including his Mastership from the America Academy of Implant Prosthodontists, Mastership and Fellowship from the International Congress of Oral Implantologists and Mastership from the prestigious Misch International Implant Institute.

Dr. Ayoub is a member of the American Dental Association, Arizona Dental Association, Academy of General Dentistry, American Academy of Implant Dentistry, American Academy of Cosmetic Dentistry and The Academy of Laser Dentistry.

For more information, please go to www.TodaysBestDentists.com or contact Dr. George R. Ayoub DDS, directly at 623-536-2040 or at http://www.mcdowelldentistryaz.com.

The "National Consumer Advisory Board" accepts no fees, sponsorships, donations or advertising in their selection process. Dentists were chosen following an application based on training, experience, continuing education, and dedication to excellence. Only Dentists that satisfy all of the board's criteria can qualify for inclusion in the "Americas Best Dentists" directory.

TodaysBestDentists.com
Americas Best Dentists
5555555555
email us here


Source: EIN Presswire

Will Rep. Price support President Trump’s campaign pledge to enable personal importation of brand—name medicines?

Questions that should be asked of HHS Designee.

A medicine that is unaffordable is inherently unavailable, and a medicine that is unavailable and not able to be afforded is a medicine that is denied”

— Daniel Hines

ST. LOUIS, MISSOURI, USA, January 30, 2017 /EINPresswire.com/ — The Publisher of RxforAmericanHealth, AmericanRxBillofRights and TodaysSeniorsNetwork, has sent an open letter to President Donald Trump and Health and Human Services Secretary Rep. Tom Price of Georgia seeking clarification on whether the designee supports the President’s campaign pledge of a role for personal importation of brand-name prescription medicines from Tier One countries as a way to lower prescription drug costs.

Hines also sent the letter to the members of the U.S. Senate.(To read the letter, click here).

“We applaud President Trump’s continued expressions of support for personal importation as evidenced by his campaign pledge, and more recently, his sharp criticism of the predatory pricing practices of Pharma that deny access to literally millions of Americans to vital medicines because the high prices render the medicines unaffordable and unavailable,” says Publisher Daniel Hines.

But, Hines continues, during the Senate Judiciary Committee hearings for Rep. Price, he and Senator Bernie Sanders (D-VT) engaged in an exchange based upon Rep. Price’s continued references to his goal being ‘accessibility’ to health care for all Americans.

“Senator Sanders correctly pointed out that accessibility is not the same as the ability to purchase or afford adequate medical care,” Hines notes.

The problem, Hines explains, is that “a medicine that is unaffordable is inherently unavailable, and a medicine that is unavailable and not able to be afforded is a medicine that is denied.”

“However, a recent article from Roll Call offers Rep. Price an opportunity to shed light on his definition of accessibility to health care, “Hines says, noting that he sought an exemption from the Food and Drug Administration seizure of medicines of a constituent.

The exemption was sought because the constituent said the price of the medicine in the U.S. was unaffordable and he turned to Canada to personally import the medicine at a much lower cost.

Roll Call noted that “…In February 2006, Rep. Price’s office appealed to the FDA on behalf of a constituent in need of a medicine for a surgery. While both drugs were available for sale in the United States, the patient was trying to import them from Canada, where they were presumably cheaper. The drugs were being held in customs, and the FDA explained to Price that it wasn’t legal to import the drugs manufactured outside of the country, even though there are some exceptions to this policy…”

Ironically, one of the exceptions under which personal importation is allowable is if the medicine is unavailable, Hines explains.

“This directly addresses the question of whether or not a medicine is unavailable if it is unaffordable, or is it ‘accessible’ if available in the U.S., but the patient can’t afford it.”

Hines notes: “When Rep. Price wrote the letter, the FDA and U.S. Customs were engaged in collusion for such seizures which were accompanied by a letter threatening the patient who personally imported their medicines that by signing the letter they were admitting they were guilty of violating the law, that they were pledging that they would not attempt to import medicines in the future, and, if they did, their signature on the Customs letter would constitute an admission of guilt.”

“I and other advocates working on behalf of the rights of Americans to have true access to safe, affordable prescription medicines worked with contacts in the Senate to have the seizures halted, and to also specifically deny funding to Customs for such seizures,” Hines says.

That is why we are asking Rep. Price to now explain if his definition of ‘access ’includes support of the rights of Americans to engage in personal importation as he sought—and failed in– on behalf of his constituent.

Another question arises from a recent letter from many Democrat members of the U.S. House of Representative to President Barrack Obama, in which they sought to “… encourage your administration to explore implementing drug importation rules that are already part of U.S. law. Under authority from the Medicare Prescription Drug Improvement and Modernization Act of 2003, the Secretary of Health and Human Services can certify the importation of prescription drugs from other countries under specific qualifications. This regulatory action would pose no risk to public health and safety and could result in a significant reduction in the cost of prescription drugs to American families.”

This leads to specific questions that should be addressed by the President and Rep. Price:

1. Will Rep. Price, if confirmed as HHS Secretary, continue his previously stated support of personal importation as exampled by his letteron behalf of a constituent turning to personal importation;
2. Does Rep. Price believe that a prescription medicine is in and of itself unavailable because it is unaffordable, thereby meeting the FDA’s stated and printed decision that a medicine or device that is unavailable is thereby exempt from restrictions of personal importation?
3. Will Rep. Price, if confirmed, follow the directive and intent of Congress as stated in the Medicare Prescription Drug Improvement and Modernization Act of 2003?

“The designee’s response to these questions is of prime importance,” Hines concludes. “The fact is that personal importation of safe, affordable medicines from Tier One countries is the most immediate relief from the predatory drug pricing practices of Pharma.”

Daniel Hines
TodaysSeniorsNetwork
6363992849
email us here


Source: EIN Presswire